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Background: Vulvar cancer is a relatively rare malignancy, which occurs most often in postmenopausal women. We
have previously identified a geographic cluster of vulvar cancer in young Indigenous women living in remote
communities in the Arnhem Land region of Australia. In this population, we investigated the prevalence of
oncogenic human papillomavirus (HPV) infection in anogenital samples (vulvar/vaginal/perianal area and cervix) and
compared the overall, type-specific and multiple infection prevalence between sites.
Methods: A cross-sectional survey of 551 Indigenous women aged 18–60 years was undertaken in 9 Arnhem Land
communities. Women were consented for HPV detection and genotyping collected by a combined vulvar/vaginal/
perianal (VVP) sweep swab and a separate PreservCyt endocervical sample collected during Pap cytology screening.
HPV DNA testing was undertaken using PCR with broad spectrum L1 consensus PGMY09/11 primers with
genotyping of positive samples by Roche Linear Array. The primary outcomes were the prevalence of cervical and
VVP high-risk (HR) HPV.
Results: The prevalence of VVP HR-HPV was 39%, which was significantly higher than the cervical HR-HPV
prevalence (26%, p<0.0001). HPV-16 was the most common genotype detected in both sites (VVP 11%, cervical 6%).
HPV-16 infection peaked in women aged <20 years; however, there was a marked decline in cervical HPV-16
prevalence with age (p=0.007), whereas following an initial decline, the prevalence of VVP HPV-16 remained
constant in subsequent age-groups (p=0.835).
Conclusions: In this population experiencing a cluster of vulvar cancer, the prevalence of cervical oncogenic HPV
infection was similar to that reported by studies of other Australian women; however there was a significantly
higher prevalence of vulvar/vaginal/perianal infection to cervical. The large discrepancy in HPV prevalence between
anogenital sites in this population may represent more persistent infection at the vulva. This needs further
investigation, including the presence of possible environmental and/or genetic factors that may impair host
immunity.
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Vulvar cancer is a relatively rare malignancy, accounting
for approximately 3% of all gynecological cancers world-
wide [1]. Two independent etiological pathways have
been implicated in the development of vulvar cancer. In
younger women, persistent infection with oncogenic
human papillomavirus (HPV), mainly genotype 16, is a
pre-requisite to the development of cancer [2]. In older,
predominantly post-menopausal women, cancer arises in
vulvar skin affected by squamous hyperplasia or lichen
sclerosus [3].
Worldwide, the incidence of vulvar cancer ranges from
0.0 to 3.5 per 100,000 [4]. Although relatively uncom-
mon, the incidence is increasing, largely in younger
women, associated with oncogenic HPV and smoking
[5-7]. In women aged less than 50 years, the highest in-
cidence rate has been reported in the Northern Territory
of Australia (2.3 per 100,000) [4]. This is largely the re-
sult of a very high incidence in young Aboriginal (Indi-
genous) women living in a distinct geographic region
known as Arnhem Land.
Between 1996–2005, in the Arnhem Land region, the
incidence of vulvar cancer among Indigenous women
aged less than 50 years was 31.1 per 100,000 (95% Confi-
dence Intervals (CI) 13.1-49.1), over 50 times higher
than the rate for the total Australian population of the
same age-group [8]. An excess of high-grade vulvar
intraepithelial neoplasia (VIN grade 2/3), the precursor
lesion to vulvar cancer also occurs in this population [8].
The cause of this very high incidence is unclear. The
cases are almost entirely restricted to the under 50 age-
group, suggesting that excess oncogenic HPV infection
is a key etiological factor. The prevalence of vulvar HPV
infection in this population and in other Australian
women is unknown. We undertook a cross-sectional
study to assess prevalence of oncogenic anogenital HPV
infection in Indigenous women residing in the Arnhem
Land region. Samples were collected from the cervix
and vulvar/vaginal/perianal area. The aims of this study
were two-fold. First, to compare the vulvar/vaginal/
perianal and cervical HPV prevalence in Arnhem Land
women. Second, to compare the prevalence of cervical
HPV in this population to that of other Australian
women, to provide an indirect indication of whether
oncogenic vulvar HPV infection is more common in the
Arnhem land region.
Methods
Participants and procedures
A cross-sectional survey was undertaken in 2007–2009
in 11 primary health centres providing services to 9 Indi-
genous communities and a number of smaller outstations
in the Arnhem Land region. The characteristics of this re-
gion have been described previously [8]. Briefly, this is asparsely populated area in the northern part of Australia.
The majority of the population are Indigenous and living
in discrete remote communities of varying population size
ranging from several hundred to approximately 2,500
people. Health centres based in the communities provide
primary health care and limited access to visiting specialist
medical services.
Communities were identified based on our earlier
work [8] and represented the majority in the region with
vulvar cancer cases. The study was preceded by an ex-
tensive period of consultation, which included holding
community forums to raise awareness of vulvar cancer.
During this time an Indigenous reference group com-
prising Indigenous women from the region was estab-
lished to advise on all aspects of the study.
Women were eligible to participate if they met the fol-
lowing criteria: Aboriginal and/or Torres Strait Islander,
aged between 18 and 60 years, and their usual place of resi-
dence was in a community in the Arnhem Land region.
There were four methods of recruitment: (1) approach-
ing women due for Pap screening based on health centre
recall systems; (2) holding community forums; (3) hold-
ing “women’s health weeks” which had a focus on health
education and screening; and (4) approaching women
who presented to the health centre when the research
team were present.
All participants gave written informed consent, and
the study procedures conformed to the principles of the
Declaration of Helsinki. Consenting women were invited
to have a Pap test, specimen collection for combined
vulvar/vaginal/perianal (VVP) and separate cervical HPV
detection and genotyping, swabs and collection of blood
(where indicated) for assessment of other sexually trans-
missible infections (STIs), and clinical examination for
vulvar lesions. Samples for VVP genotyping were col-
lected by clinical staff performing a single sweep swab of
the vulva, vagina and peri-anal region using an estab-
lished protocol [9]. The VVP swab was undertaken be-
fore the Pap test. Samples for endocervical HPV
genotyping were taken from the PreservCyt endocervical
sample collected during Pap screening. The endocervical
sample was collected prior to any other swabs of the cer-
vix or posterior fornix, using an endocervical brush that
was removed carefully to avoid vaginal contamination.
The majority (75%) of specimens were collected by the
same clinician (MN).
Women with clinical signs of anogenital disease were
referred to a gynecologist for colposcopy and biopsy for
definitive histological diagnosis and treatment. Abnor-
mal Pap and STI test results were managed by the health
centre in accordance with local guidelines. Women test-
ing positive for high-risk (HR) HPV but with a normal
Pap test result were offered a repeat Pap test and HPV
genotyping at 12 months.
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For cervical and VVP specimens, cellular and viral DNA
was extracted using the MagNA Pure LC (MP) isolation
and purification system (Roche Molecular Systems Ala-
meda, CA, USA) with a modified protocol [10]. For
cervical specimens, HR-HPV was detected using the
Amplicor HPV test (Roche Molecular System) targeting
165 bp of the L1 gene of the 13 HR-HPV anogenital
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68). Sample adequacy was determined as the Amplicor
PCR method allows for simultaneous amplification of
~265 bp region of human ß-globin.
Any samples negative for HR-HPV on the Amplicor
HPV test were further assessed for the presence of HR-
and low risk (LR)-HPV. Briefly, 20 uL of extracted DNA
was amplified for 40 cycles using 50 rmol of each of the
Ll consensus primers PGMY09/11 [11,12]. Amplification
products were hybridised with a biotin-labelled HPV Ll
generic probe [13] and captured on streptavidin-coated
plates (Roche Biochemicals) [14]. The bound hybrid was
detected by an anti-digoxigenin peroxidase conjugate by
use of the colourimetic substrate ABTS [14].
HPV DNA genotyping
Any sample positive for HR- or LR-HPV DNA was geno-
typed on the Roche Linear Array (LA) HPV genotyping
test (Roche Molecular Systems). This test directs amplifi-
cation of a 450 bp region of the HPV L1 gene and allows
identification of 37 anogenital HPV genotypes (6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84,
IS39 and CP6108) as well as amplification of 265 bp re-
gion of the human ß-globin gene, serving as an internal
control. Samples were denatured and detected using a
modified method as previously described [15,16]. Due to
possible cross-reactivity of the HPV-52 probe with types
33, 35, and 58 amplicons, samples positive for the HPV-
52 probe alone were classified as HPV-52 positive, whilst
those reactive with this probe and one or more of HPV-
33, 35, and 58 probes were further tested using a real-
time PCR assay with an HPV-52 specific hydrolysis
probe [17], allowing detection of HPV-52 DNA in the
presence/absence of other genotypes.
At the completion of the study any cervical or VVP
sample that was positive on any test had the correspond-
ing cervical or VVP sample genotyped to ensure correct
comparison of differing samples. There were 10 cervical
samples and 5 VVP samples that were positive on initial
HPV DNA testing, but no HPV genotype was detected
on LA.
Primary outcomes
The primary outcomes were the cervical and VVP
prevalence of HR-HPV, defined as detection of any oneof the following HPV types: 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58 or 59). Secondary outcomes included the cer-
vical and VVP prevalence of: probable HR-HPV (type
68), possible HR-HPV (types 26, 53, 66, 67, 69, 70, 73 or
82), any-HPV (presence of any of the 37 types detectable
on LA), LR-HPV (types 6, 11, 40, 42, 54, 55, 61, 62, 64,
71, 72, 81, 83, 84, CP6108, IS39), multiple HR types,
multiple LR types, individual type-specific HPV and vac-
cine preventable types (6, 11, 16, 18). All HPV preva-
lence figures were based on HPV as detected on LA.
HPV types were classified into carcinogenic groups
according to the International Agency for Research on
Cancer [18].Analyses and sample size
Proportions and means/medians were calculated to
summarize the data as appropriate. As there is no data
on the prevalence of vulvar HPV infection in Australian
women, we compared the prevalence of cervical HR-
HPV infection in Arnhem Land women to that of other
Australian women (Indigenous and non-Indigenous)
based on the results of the Women's HPV prevalence
Indigenous Non-Indigenous Urban Rural Study (WHI-
NURS) [19]. This is a national study of cervical HPV
genotype prevalence undertaken between 2005–08 by
members of the research team (JRC, SNT, SMG) using
the same methodology (sample collection and analysis)
and the same laboratory for HPV genotyping as this
study. The McNemar’s matched pairs test was used to
assess whether the prevalence of VVP HPV was similar
to the prevalence of cervical HPV infection, in women
with both samples adequate for HPV analysis. This com-
parison was made to provide an indirect indication of
whether VVP HPV infection is more common in Arn-
hem Land women than other Australian women. Chi-
square analysis was undertaken to assess whether HPV
prevalence varied across 10-year age bands. Where the
expected cell counts were less than 5, the exact signi-
ficance probability is reported. A P-value <0.05 was
considered statistically significant. All analyses were con-
ducted using Stata version 10.0 (Stata Corporation, Col-
lege Station, TX, USA).
The sample size was estimated using preliminary data
in 2006 from the WHINURS [19]. To detect a differ-
ence in the prevalence of HPV-16 and 18 combined of
14.5% for Indigenous women in Arnhem Land com-
pared with the 9.5% found in the WHINURS, 521
women were required (alpha level 0.05, 80% power,
one-sided test).
This study was approved by the Human Research Eth-
ics Committee of the Menzies School of Health Research
and the Northern Territory Department of Health and
Community Services, and its Aboriginal subcommittee.
Table 2 Vulvar abnormalities, cervical cytology, and
sexually transmissible infections detected at study
examination
N=551 %
Suspected vulvar abnormality 20 3.6
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Five-hundred and sixty-two women consented to partici-
pate. Eleven women (1.9%) were found to be ineligible
after enrolment due to age and were excluded. The char-
acteristics of participants are summarised in Table 1.
Fifty-three women (9.6%) had never previously had a
Pap smear. Two women (0.4%) presented with current
anogenital symptoms.
All women consented to a vulvar examination and
VVP swab collection. However, VVP samples were not
adequate for HPV testing for 30 women, due to samples
leaking during transportation. Five-hundred and nine
women consented to Pap screening, and of these, cer-
vical samples were not adequate for HPV testing in two
women. A vault smear was undertaken in six women
with a hysterectomy, and these samples were excluded
from the cervical samples. As a result, a total of 521
VVP swabs and 501 cervical swabs were adequate for
analysis.
On examination, one new case of vulvar cancer and
two new cases of high-grade vulvar lesion were found;
six definitive high-grade cervical lesions were detectedTable 1 Demographic characteristics, previous anogenital
neoplastic lesions, and history of chronic disease among
participating women
Characteristics N=551 %
Mean age, years (SD) 34.5 10.7
Median BMI, kg/m2 (IQR) 22.8 19.2-26.9
Current smoker 368 66.8
On hormonal contraception 220 39.9
Any previous anogenital dysplastic/neoplastic lesion* 168 30.5
cervical low grade lesion 142 25.8
cervical high-grade lesion 75 13.6
invasive cervical cancer 1 0.2
vulvar intraepithelial neoplasia 3 0.5
invasive vulvar cancer 2 0.4
vaginal intraepithelial neoplasia
or invasive vaginal cancer
0 0
anal intraepithelial neoplasia 0 0
invasive anal cancer 2 0.4
Vulvectomy 2 0.4
Hysterectomy 19 3.4
Diabetes 54 9.8
Chronic renal disease 38 6.9
Acute rheumatic fever 24 4.4
Asthma 22 4.0
Autoimmune disease 15 2.7
Chronic liver disease 4 0.7
Figures are n, % unless otherwise indicated.
*Histologically confirmed.
SD = standard deviation, IQR = interquartile range, BMI= body mass index.on Pap cytology screening (Table 2). No new anal lesions
were identified.HPV prevalence
The prevalence of VVP HR-HPV was 39% compared
with the cervical HR-HPV prevalence of 26% (Table 3).
Co-infection with multiple VVP HR-HPV types occurred
in 15% of women, and 6% had multiple cervical HR-
HPV types. HPV-16 was the most common genotype
detected in both the cervix and the VVP area (Table 3).
Of the vaccine preventable types, the prevalence of type
16 and/or 18 was 13% in the VVP area and 7% in the
cervix; types 6, 11, 16 and/or 18 were in 15% of women
in the VVP area and 8% in the cervix.Confirmed vulvar abnormality 9 1.6
low grade VIN 3 0.5
high-grade VIN* 2 0.4
invasive vulvar cancer* 1 0.2
genital warts 1 0.2
other (e.g. trauma, non-specific inflammation) 3 0.5
Pap test performed 509 92.4
thin prep and/or slide 502 91.1
vault smear 7 1.3
Satisfactory Pap specimen† 501 98.4
Pap result normal{ 464 92.6
Abnormal Pap results{ 37 7.4
possible LGSIL 19 3.8
definite LGSIL 8 1.6
possible HGSIL 4 0.8
definite HGSIL 6 1.2
Sexually transmissible infections
positive for N. gonorrhoeae} 19 3.9
positive for C. trachomatis} 25 5.1
positive for T. vaginalis} 132 26.9
positive for active syphilis (T. pallidum)} 11 2.5
previous positive for past and/or treated syphilis} 76 17.3
HIV** 0 0
*One woman had a high-grade and an invasive cancerous lesion on the vulva.
†Of n=509 Pap tests performed.
{Of n=501 satisfactory Pap specimens.
}Of n=491 tests.
}Of n=439 tests.
**Of n=428 tests.
VIN = vulvar intraepithelial neoplasia, LGSIL = low-grade squamous
intraepithelial lesion, HGSIL = high-grade squamous intraepithelial lesion,
SCC = squamous cell carcinoma, HIV = human immunodeficiency virus.
Table 3 Prevalence and distribution of HPV DNA detected
in cervical and vulvar/vaginal/perianal samples (n=1022)
HPV type Cervical Vulvar/vaginal/
perianal
n=501 % n=521 %
HR types* 130 25.9 201 38.6
Multiple HR types 29 5.8 80 15.4
Probable HR type (genotype 68)† 8 1.6 14 2.7
Possible HR types{ 47 9.4 117 22.5
Multiple possible HR types{ 5 1.0 12 2.3
Any HPV 221 44.1 334 64.1
Multiple HPV types 81 16.2 209 40.1
Any LR types 108 21.6 213 40.9
Multiple LR types 23 4.6 89 17.1
Individual HR types*
16 29 5.8 58 11.1
51 22 4.4 49 9.4
52 20 4.0 38 7.3
58 17 3.4 28 5.4
35 11 2.2 24 4.6
39 18 3.6 24 4.6
56 8 1.6 24 4.6
59 12 2.4 21 4.0
18 8 1.6 15 2.9
45 6 1.2 11 2.1
33 7 1.4 10 1.9
31 6 1.2 9 1.7
Individual possible HR types{
53 28 5.6 59 11.3
70 6 1.2 25 4.8
66 8 1.6 16 3.1
69 6 1.2 12 2.3
73 4 0.8 11 2.1
26 0 - 2 0.4
67 0 - 2 0.4
82 0 - 2 0.4
Individual LR types
81 24 4.8 57 10.9
62 19 3.8 50 9.6
72 20 4.0 38 7.3
84 16 3.2 35 6.7
55 14 2.8 28 5.4
71 6 1.2 25 4.8
42 8 1.6 19 3.6
54 5 1.0 17 3.2
61 4 0.8 17 3.2
CP6108 6 1.2 16 3.1
IS39 2 0.4 9 1.7
83 7 1.4 8 1.5
Table 3 Prevalence and distribution of HPV DNA detected
in cervical and vulvar/vaginal/perianal samples (n=1022)
(Continued)
6 5 1.0 6 1.2
40 4 0.8 5 1.0
11 0 - 4 0.8
64 0 - 0 -
*IARC Group 1, †IARC Group 2A, {IARC Group 2B.
HPV=human papillomavirus, HR=high-risk, IARC=international agency for
research on cancer, LR=low-risk.
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ples (cervical and VVP) adequate for HPV analysis. The
prevalence of HR-HPV was significantly higher in the
VVP samples than the cervical samples (39% vs 26%,
p<0.0001), as was the presence of multiple HR-HPV
types (16% vs 6%, p<0.0001) and possible HR-HPV types
(22% vs 10%, p<0.0001).Type-specific HPV prevalence
was significantly higher in the VVP samples for the fol-
lowing HR-HPV types: 16 (11% vs 6%, p<0.0001), 51
(10% vs 4%, p<0.0001), 52 (8% vs 4%, p=0.002), 56 (5%
vs 1%, p=0.0001) and 35 (5% vs 2%, p=0.004); and pos-
sible HR-HPV types: 53 (11% vs 6%, p<0.0001), 70 (4%
vs 1%, p=0.0001) and 73 (2% vs 1%, p=0.03).
Age-specific HR-HPV and HPV-16 prevalence
For both VVP and cervical infections, HR-HPV preva-
lence peaked in the age-group <20 years and declined
thereafter (Figure 1). There was a significant difference
in the age distribution of cervical HR-HPV (p=0.001);
the difference in age distribution of VVP HR-HPV was
of borderline statistical significance (p=0.06). A different
pattern was observed for the age-specific prevalence of
HPV-16 infection. There was a marked and significant
decline in prevalence of cervical HPV-16 infection with
age (p=0.007), whereas VVP HPV-16 infection declined
initially after the <20 age-group and then remained con-
stant across the older age-groups (p=0.835) (Figure 1).
Discussion
In this community-based study of Indigenous women in
the Arnhem Land region, where there is a very high inci-
dence of vulvar neoplasia [8], genital HPV infection was
common, and significantly more prevalent and more di-
verse in the VVP area than the cervix. HPV-16 was the
most common genotype detected in both sites, and in
general the type-specific prevalence of HPV infection
was significantly higher in the VVP area relative to the
cervix for both oncogenic and LR-HPV types.
Just over a quarter of all women in this study had a cer-
vical HR-HPV infection, which is very similar to the preva-
lence found in the WHINURS, the largest examination of
cervical HPV genotype prevalence in Australian women
(cervical HR-HPV prevalence 30.0% in non-Indigenous
Figure 1 Age-specific prevalence of VVP and cervical HR-HPV
and HPV-16.
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[19]. In our study population, we found a significantly
higher prevalence of HR-HPV infection in the VVP area
than the cervix. These findings suggest that there is no ex-
cess prevalence of oncogenic cervical infection amongst In-
digenous women in Arnhem Land. Vulvar/vaginal/perianal
infection was not assessed in the WHINURS.
A higher rate of HPV detection in vulvar/vaginal sam-
ples than cervical samples has been reported previously
[20,21]: however, the discrepancy between anogenital
sites found in this study is substantially higher than in
previous studies. We found the prevalence of any HPV
and HR-HPV in the VVP area was 1.5 times higher than
in the cervix (absolute differences 20% and 13%, respect-
ively), whereas previous studies report a higher preva-
lence in vulvar/vaginal samples than cervical in the
order of 1.2 times for any HPV and 1.1 times for HR-
HPV (absolute differences ranging from 2-6% and 1-5%,
respectively) [20,21], or no difference between genital
sites [22-24].
The higher prevalence of VVP infection may reflect
increased persistence of infection or continuing re-
infection with different genotypes. Our finding that VVP
HPV-16 prevalence did not vary significantly by age,
whereas there was a marked and significant decline in
cervical HPV-16 prevalence, suggests that increased per-
sistence of HR types on the vulva alone may be occur-
ring. This may explain why the cervical cancer incidence
in this population is no higher than in other Indigenous
women in the Northern Territory [25]. We are not
aware of any other reports of increased persistent in-
fection in other genital sites than the cervix, although
increased persistence in the anus relative to the cervix
has been reported in immunocompromised women [26].The higher prevalence of infection in the VVP area
relative to the cervix could also reflect incident infec-
tions that have not yet ascended to the cervix. Winer
et al. [27] demonstrated a shorter interval between re-
port of a new sex partner and HPV infection for geno-
types on the vulva/vagina than cervix. This is unlikely to
completely explain the higher prevalence seen in this
study as a subsequent report by the same group found
the majority of incident infections were still detected
simultaneously in both sites [28]. Also, the relatively lar-
ger surface area swabbed for the VVP sample than the
cervix may have resulted in enhanced detection of HPV
[29]. Although if this were the primary reason for the
higher prevalence, a smaller difference between sites
consistent with previous studies of genital HPV would
be expected [20,21]. The higher prevalence observed in
the VVP sample could also reflect contamination from
or oversampling of the perianal region, as a higher
prevalence of anal HPV than cervical has been reported
in high-risk women [30].
Longitudinal data are needed to examine persistence
of VVP HPV infection in this population. However,
while speculative, neither a 1.5-fold higher prevalence
nor increased persistence of HR-HPV types is likely to
be sufficient to explain the fifty-times higher incidence
of vulvar cancer in this population compared to other
Australian women. Other factors that alter the balance
between HPV infection and host immunity are likely to
be present. Such factors could be genetic, affecting the
susceptibility to or inability to clear HPV, or environ-
mental, possibly altering the natural history of infection
of the vulvar epithelium. An interaction between a com-
bination of risk factors (e.g. genetic, HPV, smoking) is
also possible; genetic variation in Th1 cytokines has
been shown to modify the risk of vulvar cancer among
smokers [31]. A very high rate of smoking was found in
this study (67%), consistent with previous data from the
Northern Territory [32]. Further research is currently
underway examining possible environmental and genetic
factors in this population.
There are several limitations of this study. There is no
data on HPV prevalence in the VVP area in other Aus-
tralian women, and so a direct comparison of VVP HPV
prevalence was not possible. The study design was
cross-sectional, therefore persistence of HPV infection
could not be adequately assessed. Similarly, detection of
HPV DNA only reflects current infection or carriage sta-
tus, hence there is no information about cumulative life-
time exposure to HPV. Some women (7%) did not
consent to have a Pap smear, which reduced the number
of women with both samples available for analysis. There
was no difference in demographic characteristics or his-
tory of anogenital lesions between women who con-
sented to a Pap smear and those who did not, suggesting
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results will not generalize to other Indigenous or non-
Indigenous women, as the study was purposely designed
to examine the prevalence of HPV in a population with,
to our knowledge, the highest incidence of vulvar cancer
reported worldwide.Conclusions
In young Indigenous women in the Arnhem Land region
of Australia, a population subject to a cluster of vulvar
cancer, we have shown that the prevalence of cervical
HPV infection is similar to other Australian women, both
Indigenous and non-Indigenous. We found a signifi-
cantly higher prevalence of vulvar/vaginal/perianal infec-
tion to cervical in Arnhem Land Indigenous women.
Although in other Australian women the prevalence of
HPV infection in the vulvar/vaginal/perianal area is un-
known, in our study population, the higher prevalence of
infection in this area relative to cervical is unlikely to
completely explain this cancer cluster. Further investiga-
tion of possible genetic and/or environmental risk factors
that may impair host immunity is required.
Abbreviations
BMI: Body mass index; DNA: Deoxyribonucleic acid; HGSIL: High–grade
squamous intraepithelial lesion; HIV: Human immunodeficiency virus;
HPV: Human papillomavirus; HR: High-risk; HR-HPV: High-risk human
papillomavirus; IARC: International agency for research on cancer;
IQR: Interquartile range; LGSIL: Low-grade squamous intraepithelial lesion;
LR: Low-risk; SCC: Squamous cell carcinoma; SD: Standard deviation;
STI: Sexually transmissible infection; VIN: Vulvar intraepithelial neoplasia;
VVP: Vulvar/vaginal/perianal; WHINURS: Women's HPV prevalence indigenous
non-indigenous urban rural study.
Competing interests
SMG has received advisory board fees and grant support from CSL and GSK;
lecture fees from Merck, GSK and Sanofi Pasteur; funding (through her
employing institution) to conduct HPV vaccine studies for MSD and GSK; and
is a member of the Merck Global Advisory Board and the Merck Scientific
Advisory Committee for HPV. SET is the recipient of a GlaxoSmithKline
Australian Postgraduate Support Grant for work outside of this submitted
manuscript. CSL Biotherapies have provided funding to the authorship group
to support a workshop on genetic susceptibility to vulvar cancer.
Authors’ contributions
JRC, ARR, SNT and SMG had a primary role in developing the study design;
DT and MN were responsible for participant recruitment, sample collection
and data management; SET undertook the HPV genotyping of samples and
all other associated laboratory work under the supervision of SNT. ARR
conducted the analyses and drafted the manuscript; JRC, SET, DT, MN, MJD,
MMO, CMC, IZ, JM and SMG contributed to the interpretation of analyses
and assisted with preparation and editing of the manuscript. All authors read
and approved the final manuscript.
Funding
This work was supported by the National Health and Medical Research
Council (NHMRC) in Australia, Grant ID: 436013. The views expressed in this
publication are those of the authors and do not reflect the views of NHMRC.
Alice Rumbold is supported by the Jean B Reid Fellowship from the
University of Adelaide Medical Endowment Funds. Sarah Tan is supported by
the Royal Women’s Hospital Post Graduate Degree Scholarship from the
Royal Women’s Hospital, Melbourne Australia.Acknowledgements
We are grateful to all of the women who participated in this study, and all of
the staff and management of the primary health centres who actively
supported this study. We would like to acknowledge the following
individuals who assisted with field work: Annette Heather, Megan Kennedy
and Leonie Conn, from the Northern Territory Department of Health.
Author details
1Discipline of Obstetrics & Gynaecology, The University of Adelaide, Adelaide,
SA 5005, Australia. 2Epidemiology and Health Systems Division, Menzies
School of Health Research, PO Box 41096, Casuarina, NT 0811, Australia.
3Clinical Microbiology and Infectious Diseases, Royal Women’s Hospital, and
Department of Obstetrics and Gynaecology, University of Melbourne, Royal
Women’s Hospital, Cnr of Flemington Road and Grattan Street, Parkville, VIC
3052, Australia. 4WHO HPV LabNet Regional Reference Laboratory - Western
Pacific Region, Melbourne, VIC, Australia. 5Health Services Division, Northern
Territory Department of Health, PO Box 40596, Casuarina, NT 0811, Australia.
6Infectious Diseases and Microbiology Group, Murdoch Children’s Research
Institute, Bio 21 Institute, Level 1 Building 404, 30 Flemington Rd, Parkville,
Victoria 3052, Australia. 7Surgical and Specialties Service, Royal Adelaide
Hospital, North Tce, Adelaide, SA 5000, Australia. 8Department of Obstetrics
and Gynaecology, Cairns Base Hospital, The Esplanade, Cairns, QLD 4870,
Australia. 9Discipline of Anatomical Pathology, University of Newcastle,
Manning Health Campus, PO Box 649, Taree, NSW 2430, Australia.
10Biostatistics Group, Menzies Research Institute Tasmania, University of
Tasmania, Medical Sciences Building 1, 17 Liverpool Street, Private Bag 23,
Hobart, TAS 7000, Australia.
Received: 11 November 2011 Accepted: 27 September 2012
Published: 5 October 2012
References
1. Sankaranarayanan R, Ferlay J: Worldwide burden of gynaecological cancer:
The size of the problem. Best Pract Res Clin Obstet Gynaecol 2006,
20(2):207–225.
2. van Beurden M, ten Kate FJ, Smits HL, Berkhout RJ, de Craen AJ, van der
Vange N, Lammes FB, ter Schegget J: Multifocal vulvar intraepithelial
neoplasia grade III and multicentric lower genital tract neoplasia is
associated with transcriptionally active human papillomavirus. Cancer
1995, 75(12):2879–2884.
3. Scurry JP, Vanin K: Vulvar squamous cell carcinoma and lichen sclerosus.
Australas J Dermatol 1997, 38(Suppl 1):S20–S25.
4. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P:
Cancer Incidence in Five Continents, Vol. IX. Lyon, France: IARC; 2007.
5. Sturgeon SR, Brinton LA, Devessa SS, Kurman RJ: In situ and invasive vulvar
cancer incidence trends (1973–1987). Am J Obstet Gynecol 1992,
166(5):1482–1485.
6. Jones RW, Ranayai JU, Stables S: Trends in squamous cell carcinoma of
the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol
1997, 90(3):448–452.
7. Iversen T, Tretli SI: Intraepithelial and invasive squamous cell neoplasia of
the vulva: Trends in incidence, recurrence and survival rate in Norway.
Obstet Gynecol 1998, 91:969–972.
8. Condon JR, Rumbold AR, Thorn JC, O’Brien MM, Davy M, Zardawi I: A
cluster of vulvar cancer and vulvar intraepithelial neoplasia in young
Australian Indigenous women. Cancer Causes Control 2009, 20(1):67–74.
9. Garland S, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter
S, Tang GWK, Ferris DG, Steben M, Bryan J, et al: Quadrivalent Vaccine
against Human Papillomavirus to Prevent Anogenital Diseases. N Engl J
Med 2007, 356:1928–1943.
10. Stevens MP, Rudland E, Garland SM, Tabrizi SN: Assessment of MagNA
pure LC extraction system for detection of human papillomavirus (HPV)
DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY
HPV tests. J Clin Microbiol 2006, 44(7):2428–2433.
11. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: The use of
polymerase chain reaction amplification for the detection of genital
human papillomaviruses. Cancer Cells 1989, 7:209–214.
12. Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget
J, Manos MM: Detection and typing of human papillomavirus in archival
cervical cancer specimens by DNA amplification with consensus primers.
J Natl Cancer Inst 1990, 82:1477–1484.
Rumbold et al. BMC Infectious Diseases 2012, 12:243 Page 8 of 8
http://www.biomedcentral.com/1471-2334/12/24313. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A,
Manos MM: Genital human papillomavirus infection in female university
students as determined by a PCR-based method. JAMA 1991,
265:472–477.
14. Layton-Henry J, Scurry JS, Planner RS, Allen D, Sykes P, Garland SM, Borg AJ,
Tabrizi SN: Cervical adenoid basal carcinoma, five cases and literature
review. Int J Gynecol Cancer 1996, 6(3):193–199.
15. Stevens MP, Garland SM, Tabrizi SN: Human papillomavirus genotyping
using a modified linear array detection protocol. J Virol Methods 2006,
135(1):124–126.
16. Tabrizi SN, Stevens M, Chen S, Rudland E, Kornegay JR, Garland SM:
Evaluation of a modified reverse line blot assay for detection and typing
of human papillomavirus. Am J Clin Pathol 2005, 123(6):896–899.
17. Stevens MP, Garland SM, Tabrizi SN: Development and validation of a real-
time PCR assay specifically detecting human papillomavirus 52 using the
Roche LightCycler 480 system. J Virol Methods 2008, 147(2):290–296.
18. Schiffman M, Clifford G, Buonaguro L: Classification of weakly carcinogenic
human papillomavirus types: addressing the limits of epidemiology at
the borderline. Infect Agent Cancer 2009, 4:8.
19. Garland SM, Brotherton JML, Condon JR, McIntyre PB, Stevens MP, Smith
DW, Tabrizi SN, on behalf of the WHINURS study group: Human
papillomavirus prevalence amongst Indigenous and non-Indigenous
Australian women prior to a national HPV vaccination program. BMC
Med 2011, 9:104.
20. Winer RL, Feng Q, Hughes JP, Yu M, Kiviat NB, O'Reilly S, Koutsky LA:
Concordance of self-collected and clinician-collected swab samples for
detecting human papillomavirus DNA in women 18 to 32 years of age.
Sex Transm Dis 2007, 34(6):371–377.
21. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen
TE, Fortenberry JD: A longitudinal study of genital human papillomavirus
infection in a cohort of closely followed adolescent women. J Infect Dis
2005, 191(2):182–192.
22. Canadas MP, Bosch FX, Junquera ML, Ejarque M, Font R, Ordonez E, de
Sanjose S: Concordance of prevalence of human papillomavirus DNA in
anogenital and oral infections in a high-risk population. J Clin Microbiol
2004, 42(3):1330–1332.
23. Goncalves MA, Randi G, Arslan A, Villa LL, Burattini MN, Franceschi S, Donadi
EA, Massad E: HPV type infection in different anogenital sites among
HIV-positive Brazilian women. Infect Agent Cancer 2008, 3:5.
24. Barzon L, Militello V, Pagni S, Franchin E, Dal Bello F, Mengoli C, Palu G:
Distribution of human papillomavirus types in the anogenital tract of
females and males. J Med Virol 2010, 82(8):1424–1430.
25. Jones C, Zhang X, Dempsey K, Schwarz N, Guthridge S: The Health and
Wellbeing of Northern Territory Women: From the Desert to the Sea. Darwin:
Department of Health and Community Services; 2005.
26. Kojic EM, Cu-Uvin S, Conley L, Bush T, Unger E, Henry K, Hammer J, Onen N,
Palefsky J, Patel P: Human Papillomavirus (HPV) Infection of the Anus is
More Diverse and Persistent than Cervical HPV infection among HIV
infection in the SUN study. Abstract #1135. In 45th Annual Meeting of the
Infectious Diseases Society of America (IDSA). San Diego, USA: IDSA; 2007.
27. Winer RL, Lee S, Hughes JP, Adam DE, Kiviat NB, Koutsky LA: Genital
Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort
of Female University Students. Am J Epidemiol 2003, 157(3):218–226.
28. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Koutsky LA: Comparison
of incident cervical and vulvar/vaginal human papillomavirus infections
in newly sexually active young women. J Infect Dis 2009, 199(6):815–818.
29. Harper DM, Longacre MR, Noll WW, Belloni DR, Cole BF: Factors affecting
the detection rate of human papillomavirus. Ann Fam Med 2003,
1(4):221–227.
30. Palefsky JM, Holly EA, Ralston MA, Da Costa M, Greenblatt RM: Prevalence
and risk factors for anal human papillomavirus infection in human
immunodeficiency virus (HIV)-positive and high-risk HIV-negative
women. J Infect Dis 2001, 183(3):383–391.
31. Hussain SK, Madeleine MM, Johnson LG, Du Q, Malkki M, Wilkerson HW,
Farin FM, Carter JJ, Galloway DA, Daling JR, et al: Cervical and vulvar
cancer risk in relation to the joint effects of cigarette smoking and
genetic variation in interleukin 2. Cancer Epidemiol Biomarkers Prev 2008,
17(7):1790–1799.
32. Chondur R, Wang Z, Guthridge S: Smoking prevalence, Northern Territory.
In Health Gains Planning Information Sheet. Northern Territory Departmentof Health; Available at: http://www.health.nt.gov.au/Health_Gains/
Publications/index.aspx (Accessed 8th March 2011); 2010.
doi:10.1186/1471-2334-12-243
Cite this article as: Rumbold et al.: Investigating a cluster of vulvar
cancer in young women: a cross-sectional study of genital human
papillomavirus prevalence. BMC Infectious Diseases 2012 12:243.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
